Overview

The Gene Technology Act 2000 was enacted to establish a regulatory system designed to protect the health and safety of people and the environment by managing risks posed by, or as a result of, gene technology. This legislation addresses the need to regulate the use of genetically modified organisms (GMOs) in Australia, ensuring that potential risks are identified and managed effectively. The Act was introduced by the Commonwealth Parliament with the policy objective of providing a robust and science-based regulatory framework for gene technology. In response to a licence application from Nuseed Pty Ltd for a field trial of genetically modified canola, the Office of the Gene Technology Regulator is inviting written submissions to finalise the Risk Assessment and Risk Management Plan (RARMP) for the trial. This consultation is intended to inform the decision on whether to issue the licence for the proposed field trial, which aims to gather data under field conditions on various aspects of the genetically modified canola's performance and characteristics.

Scope and Application

The Act pertains to the assessment and regulation of genetically modified organisms (GMOs) within Australia, specifically focusing on a field trial of genetically modified canola proposed by Nuseed Pty Ltd. This trial, which involves plants genetically modified for altered oil content and herbicide tolerance, is intended to gather data under field conditions and is not intended for commercial use in human food or animal feed. The geographic scope of this Act encompasses potential trial sites within 95 local government areas across New South Wales, Victoria, and Queensland. The field trial is proposed to span five growing seasons, from November 2018 to December 2023, with a maximum of 150 hectares planted annually across up to 20 sites. The Act operates within the jurisdiction of the Commonwealth, under the purview of the Gene Technology Regulator, who is responsible for assessing the associated risks and determining whether to issue a licence for the trial. Submissions to the Risk Assessment and Risk Management Plan are invited to inform the final decision on the licence, with a closing date of 26 July 2018. This consultation process ensures that the potential risks to human health and the environment are thoroughly evaluated before any approval is granted.

Key Provisions

The primary sections of the legislation in question (C2018G00452) involve the assessment and potential approval of a genetically modified (GM) canola field trial (section 1). The application for this trial, submitted by Nuseed Pty Ltd under licence application DIR 163, seeks to conduct a field trial of GM canola plants genetically modified for altered oil content and herbicide tolerance. The trial aims to collect data under field conditions regarding various aspects such as agronomic performance, oil profile and content, nutritional assessment, compositional analysis, molecular analysis, and genetic stability. The trial is proposed to be conducted over five growing seasons, with a maximum of 150 hectares planted annually across up to 20 sites within 95 possible local government areas in New South Wales, Victoria, and Queensland. The obligations imposed by this legislation primarily rest on the Gene Technology Regulator, who is tasked with assessing the application and determining whether to issue the licence for the field trial. The Regulator must consider the Risk Assessment and Risk Management Plan (RARMP), which concludes that the proposed release poses negligible risk to human health and safety or the environment. The draft licence conditions, which will form part of the final decision, aim to limit the size, locations, and duration of the release, as well as restrict the spread and persistence of the GMOs and the introduced genetic material. Additionally, the Regulator is obligated to review and consider written submissions from the public to finalise the RARMP and inform the decision on the licence. In terms of potential breaches and consequences, the legislation does not explicitly outline specific offences, penalties, or consequences for non-compliance within the provided text. However, it is reasonable to infer that any failure to adhere to the approved conditions of the licence or the RARMP could result in legal action. This could include civil penalties for non-compliance with the conditions set out in the licence or criminal penalties if the non-compliance is deemed to pose a significant risk to human health and safety or the environment. The exact penalties would depend on the severity and nature of the breach, as outlined in other relevant legislation governing gene technology and environmental protection.